Company profile
Cognition Therapeutics, Inc.
NASDAQ: CGTX · Healthcare · Biotechnology
PublicHQ Purchase, NYCIK 0001455365Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 45DQ —GM —SS 37
v0.1 · 35/100 weight · pillars only
↑ filing timeliness, balance-sheet leverage · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$23.5M
Employees
14
as of 2026-08-18
Market cap
$89.1M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$23.5M-$23.5M2025
Operating income-$47.8M-$47.8M2025
Total assets$48.4M$48.4M2025
Liabilities$14.1M$14.1M2025
Equity$34.3M$34.3M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cognition Therapeutics, Inc.’s financial profile?
Cognition Therapeutics, Inc. earned -$23.5M in FY2025 net income.
Peers · Healthcare
Biomea Fusion, Inc.——Park Dental Partners, Inc. Common Stock——Hemab Therapeutics Holdings, Inc. Common Stock——Acrivon Therapeutics, Inc. Common Stock——NDT Pharmaceuticals Inc.——Aldeyra The——Key facts
CEOLisa Ricciardi
SectorHealthcare
IndustryBiotechnology
HeadquartersPurchase, NY
ExchangeNASDAQ: CGTX
Employees14
IPO date2021-10-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.